Cathie Wood’s ARK Invest sold 78,211 shares of BioNTech on July 8, 2026. The transaction was valued at approximately $7.4 million. ARK Invest reported the trade on July 9.
The ARK Genomic Revolution ETF (ARKG) executed the sale. Proceeds from the divestment funded purchases in SpaceX.
The sale occurred despite a recent legal victory for BioNTech and partner Pfizer. Europe’s Unified Patent Court dismissed a patent infringement lawsuit regarding the companies' mRNA COVID-19 vaccine.
This transaction signals a notable shift in institutional holdings for the fund manager.